Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Boehringer Ingelheim
Moodys
AstraZeneca
Colorcon

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for AZD-8055

See Plans and Pricing

« Back to Dashboard

Drug Development Status for AZD-8055: Patents, clinical trial progress, indications

AZD-8055 is an investigational drug.

There have been 30 clinical trials for AZD-8055. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2010.

The most common disease conditions in clinical trials are Lung Neoplasms, Adenocarcinoma, and Ovarian Neoplasms. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Samsung Medical Center.

There are fifty-one US patents protecting this investigational drug and five hundred and seventy-five international patents.

Recent Clinical Trials for AZD-8055
TitleSponsorPhase
Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerNational Cancer Institute (NCI)Phase 2
Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerM.D. Anderson Cancer CenterPhase 2
Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian CancerAstraZenecaPhase 2

See all AZD-8055 clinical trials

Clinical Trial Summary for AZD-8055

Top disease conditions for AZD-8055
Top clinical trial sponsors for AZD-8055

See all AZD-8055 clinical trials

US Patents for AZD-8055

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD-8055   Start Trial Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines Signal Pharmaceuticals, LLC (San Diego, CA)   Start Trial
AZD-8055   Start Trial Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH)   Start Trial
AZD-8055   Start Trial Antibody drug conjugates Novartis AG (Basel, CH)   Start Trial
AZD-8055   Start Trial Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors KuDOS Pharmaceuticals Limited (London, GB)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD-8055

Drugname Country Document Number Estimated Expiration Related US Patent
AZD-8055 European Patent Office 3131552 2034-04-16   Start Trial
AZD-8055 Japan 2017514806 2034-04-16   Start Trial
AZD-8055 Japan 2019070012 2034-04-16   Start Trial
AZD-8055 New Zealand 629860 2034-04-16   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Merck
McKinsey
Moodys
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.